ceftriaxone kabi 2 g infusioonilahuse pulber
fresenius kabi polska sp. z o.o. - tseftriaksoon - infusioonilahuse pulber - 2g 5tk; 2g 10tk
gemcitabine kabi 38 mg/ml infusioonilahuse kontsentraat
fresenius kabi polska sp. z o.o. - gemtsitabiin - infusioonilahuse kontsentraat - 38mg 1ml 52.6ml 1tk; 38mg 1ml 5.26ml 1tk; 38mg 1ml 26.3ml 1tk
gemcitabine medac infusioonilahuse kontsentraat
medac gesellschaft für klinische spezialpräparate mbh - gemtsitabiin - infusioonilahuse kontsentraat - 38mg 1ml 26.3ml 5tk; 38mg 1ml 26.3ml 1tk; 38mg 1ml 5.3ml 1tk; 38mg 1ml 52.6ml 5tk; 38mg 1ml 52.6ml 1tk
gemcitabine kabi 40 mg/ml infusioonilahuse kontsentraat
fresenius kabi oncology plc - gemtsitabiin - infusioonilahuse kontsentraat - 40mg 1ml 50ml 1tk; 40mg 1ml 25ml 1tk; 40mg 1ml 5ml 1tk
irinotecan fresenius infusioonilahuse kontsentraat
fresenius kabi polska sp. z o.o. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 5ml 1tk; 20mg 1ml 15ml 1tk
lacosamide ucb
ucb pharma s.a. - lakosamiid - epilepsiad, osaline - antiepileptics, - lacosamide ucb on näidustatud monotherapy ja adjunctive ravi ravi osaline algusega krambid koos või ilma sekundaarse teha üldistusi täiskasvanud, noorukid ja lapsed alates 4-aastastel epilepsia.
ontozry
angelini pharma s.p.a - cenobamate - epilepsia - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
pregabalin zentiva
zentiva, k.s. - pregabaliin - anxiety disorders; epilepsy - antiepileptics, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetam - epilepsia - antiepileptics, - briviact on näidustatud adjunctive ravi ravi osaline algusega krambid koos või ilma sekundaarse teha üldistusi täiskasvanud ja noorukieas patsientidel alates 16 aasta vanusest, kellel epilepsia.